Failed again: Sanofi's Ablynx reports PhII lupus flop
After losing its high-profile rheumatoid arthritis partnership just two years earlier, Sanofi’s Belgium-based biotech Ablynx could once again put an AbbVie pact on the chopping block after posting a Phase II flop this morning.
Ablynx reported out bad news that vobarilizumab disappointed yet again, failing to meet its primary endpoints in a Phase II lupus study. It’s the same drug that fizzled in RA, which AbbVie punted back in 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.